Idorsia Ltd. re-issues its full year 2023 financial guidance and expects a US GAAP operating loss of around CHF 735 million and a non-GAAP operating loss of around CHF 650 million for 2023 ? unforeseen events excluded and taking into account the ongoing cost reduction initiative in connection with the review of the research and development pipeline and product portfolio.